Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 16 Issue 11, November 2019

This issue includes a Review on precision oncology in advanced prostate cancer and a Perspective on landmarks in the development of vaginal mesh.

Image of prostate cancer patient-derived organoids supplied by Hatem Sabaawy, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. Cover design: Patrick Morgan.

Editorial

  • Advertisement

Top of page ⤴

Comment

  • The future of urology holds promising new technologies but also a challenging increase in urological care needs. To translate emerging technologies and medical advances into use and accommodate the growing demand for urological services, we need strong collaboration with other health-care professionals within urology, other medical specialties and the community that surrounds our profession.

    • Alexander B. Nolsøe
    • Peter B. Østergren
    • Mikkel Fode

    Collection:

    Comment
  • As a field that embraces technology, urology has evolved quickly in the past 15 years and is likely to change at an even greater pace in the next 15. Several approaches and initiatives have the potential to improve patient care, in particular the use of telemedicine, improvements in data analytics and growth of physician collaboratives.

    • Chad Ellimoottil

    Collection:

    Comment
Top of page ⤴

Research Highlights

Top of page ⤴

News & Views

  • Clinical and pathological risk grouping defines management in localized prostate cancer. Recent work suggests men with high-risk prostate cancer can be further subdivided into three risk groups (favourable high-risk, standard high-risk and very-high-risk) and that these groups correlate with measures of genomic risk, testing of which is increasingly being integrated into risk prediction.

    • Bashir Al Hussein Al Awamlh
    • Jonathan E. Shoag
    News & Views
  • In a recently published study, surveys of transgender individuals on hormone therapy provide insight into the self-reported effects of medication where previous thinking was only speculative. Still, controlled studies are required to avoid overinterpreting the clinical significance of specific findings in the context of what might be expected in the general population.

    • Joshua D. Safer

    Collection:

    News & Views
Top of page ⤴

Reviews

  • A number of targetable molecular alterations and resistance mechanisms have been identified in metastatic castration-resistant prostate cancer (mCRPC). As our understanding of the genomic landscape of mCRPC increases, biomarker-driven clinical trials investigating targeted therapies will enable an increasingly personalized approach to its treatment.

    • Sheng-Yu Ku
    • Martin E. Gleave
    • Himisha Beltran
    Review Article
  • The molecular mechanisms involved in papillary renal cell carcinoma (pRCC) development and drug resistance are diverse. In this Review, the authors summarize the current understanding of the mechanisms of resistance to currently used therapies in pRCC and make recommendations for future preclinical and clinical studies.

    • Anna Brodziak
    • Paweł Sobczuk
    • Anna M. Czarnecka
    Review Article
Top of page ⤴

Perspectives

  • In this timeline, the authors describe the evolution of the use of polypropylene mesh in female pelvic floor surgery. They detail how the material properties of mesh relate to the occurrence of complications and discuss approaches to developing new materials and tissue engineering techniques.

    • Naşide Mangir
    • Betül Aldemir Dikici
    • Sheila MacNeil
    Perspective
Top of page ⤴

Search

Quick links